Phenylalanine inhibition of the phosphorylation of cytoskeletal proteins from cerebral cortex of young rats is prevented by alanine

European Journal of Clinical Investigation

Volumn 30, Issue 6, 2000, Pages 536-542

  Carreras, A L ^a   De Mattos Dutra, A ^a   Meirelles, R ^a   Da Rocha, B B ^a   Wannmacher, C M D ^a   Pessoa Pureur, Regina ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Alanine; Cytoskeleton; Neurofilament; Phenylalanine; Phosphorylation; Tubulins

Indexed keywords

ALANINE; CYTOSKELETON PROTEIN; PHENYLALANINE; PHOSPHORUS 32;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; NEWBORN; NONHUMAN; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

AGE FACTORS; ALANINE; ANIMALS; CEREBRAL CORTEX; CYTOSKELETAL PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; NEUROFILAMENT PROTEINS; PHENYLALANINE; PHENYLKETONURIAS; PHOSPHORUS RADIOISOTOPES; PHOSPHORYLATION; RATS; RATS, WISTAR; TUBULIN;

EID: 0034038363     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2000.00669.x     Document Type: Article

References (34)

1. 1 Shah SN, Peterson NA, McKean CM. Lipid composition of human cerebral white matter and myelin in phenylketonuria. J Neurochem 1972;19:2369-76.
2. 2 Bauman ML, Kemper TL. Morphologic and histoanatomic observations of the brain in untreated phenylketonuria. Acta Neuropathol 1982;58:55-63.
3. 3 Hommes FA. On the mechanism of permanent brain dysfunction in hyperphenylalaninemia. Med Metab Biol 1991;46:277-87.
4. 4 Scriver CR, Kaufman S, Eisensmith RC, Woo SLC. The hyperphenylalaninemias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th Edn. New York: McGraw-Hill, Inc.;1995.p.1015-75.
5. 5 Rubin MA, Wannmacher CMD, Valente GB, Camargo MM, Pessoa-Pureur R. Diminished concentration of the NF-H subunit of neurofilaments in cerebral cortex of rats chronically treated with proline, methylmalonate and phenylalanine plus alphamethylphenylalanine. J Inher Met Dis 1992;15:252-60.
6. 32P into cytoskeletal proteins. Neurochem Int 1995;26:381-5.
7. 32P into cytoskeletal proteins from cerebral cortex of developing rats. Exp Neurol 1997;143:188-95.
8. +-ATPase activity in the synaptic plasma membrane from the cerebral cortex of rats subjected to chemically induced phenylketonuria. Med Sci Res 1995;23:261-2.
9. +-ATPase in synaptic plasma membranes from cerebral cortex of rats. Biochem Soc Trans 1995;23:227S.
10. +-ATPase activity by phenylalanine and phenyllactate in the synaptic plasma membrane from the cerebral cortex of rats. Med Sci Res 1998;26:141-3.
11. 11 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1977;72:248-54.
12. 12 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-7.
13. 13 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
14. 14 Saunders WS. Action of the ends of microtubules. Curr Op Cell Biol 1999;11:129-33.
15. 15 Williamson TL, Bruijn LI, Zhu Q, Anderson KL, Andersen SD, Julien J-P et al. Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amiotrophic lateral sclerosis-linked superoxide dismutase I mutant. Proc Natl Acad Sci USA 1998;95:9631-6.
16. 16 Morris JR, Lasek RJ. Stable polymers of the axonal cytoskeleton: The axoplasmic ghost. J Cell Biol 1982;92:192-8.
17. 17 Hoffman PN, Griffin JW, Price DL. Control of axonal caliber by neurofilament transport. J Cell Biol 1984;99:705-14.
18. 18 Ohara O, Gahara Y, Miyake T, Teraoka H, Kitamura T. Neurofilament deficiency in quail caused by nonsense mutation in neurofilament-L gene. J Cell Biol 1993;121:387-95.
19. 19 Eyer J, Peterson A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-β-galactosidase fusion protein. Neuron 1994;12:389-405.
20. 20 Moreau V, Way M. In vitro approaches to study actin and microtubule dependent cell processes. Curr Op Cell Biol 1999;11:152-8.
21. 21 Gundersen GG, Cook TA. Microtubules and signal transduction. Curr Op Cell Biol 1999;11:81-94.
22. 22 Vale RD, Schmapp BJ, Mitchison T, Stever E, Reese TS, Sheetz MP. Different axoplasmic proteins generate movement in opposite directions along microtubules in vitro. Cell 1985;43:623-32.
23. cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics. Proc Natl Acad Sci USA 1997;94:5084-9.
24. 24 Morishima-Kawashima M, Kosik KS. The pool of MAP kinase associated with microtubules is small but constitutively active. Mol Biol Cell 1996;7:893-905.
25. 25 Sontag E, Nunbhakdi-Craig V, Bloom GS, Mumby MC. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle. J Cell Biol 1995;128:1131-44.
26. 26 Miyasaka H, Okabe S, Ishiguro K, Ushida T, Hirokawa N. Interaction of the tail domain of high molecular weight subunits of neurofilaments with the COOH terminal region of tubulin and its regulation by tau protein kinase II. J Biol Chem 1993;268:22695-702.
27. 27 Bick U, Fahrendorf G, Ludolph AC, Vassallo P, Weglage J, Ullrich R. Disturbed myelination in patients with treated hyperphenylalaninemia: Evaluation with magnetic resonance imaging. Eur J Pediatr 1991;150:185-9.
28. 28 Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 1990;65:472-8.
29. 29 Thompson AJ, Smith I, Brenton D, Yaul BD, Rylance G, Davidson DC et al. Neurological deterioration in young adults with phenylketonria. Lancet 1990;336:602-5.
30. 30 Lou HC, Toft PB, Andresen J, Mikkelsen I, Olsen B, Guttler F et al. An occipitotemporal syndrome in adolescents with optimally controlled hyperphenylalaninemia. J Inher Metab Dis 1992;15:687-96.
31. 31 Zeman J, Pijackova A, Behulova J, Urge O, Saligova H, Hyanek J. Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study Eur J Pediatr 1996;155 (Suppl. 1):S56-8.
32. 32 Krouse W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D et al. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. J Clin Invest 1985;75:40-8.
33. 33 Lou HC, Lykkelund C, Gerdes AM, Udesen H, Bruhn P. Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 1987;76:560-5.
34. 34 Marsden D, Barshop BA, Capistrano-Estrada S, Rice M, Prodanus C, Sartoris D et al. Anabolic effect of human hormone: Management of inherited disorders of catabolic pathways. Biochem Med Metab Biol 1994;52:145-54.